Intellia TherapeuticsNTLA +1.64%70 Median PS Value is $20.10 as of Jun. 24, 2026, which is 3692% above its 10-year median of 0.53. GuruFocus rates NTLA with a GF Score™ of 70/100 and a GF Value™ of $20.67 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 276 Biotechnology companies, Intellia Therapeutics ranks worse than 61.96% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Intellia Therapeutics's Median PS Value or its related term are showing as below:
NTLA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.41 Med: 0.53 Max: 0.8
Current: 0.77
During the past 12 years, the highest Price to Median PS Value of Intellia Therapeutics was 0.80. The lowest was 0.41. And the median was 0.53.
NTLA's Price-to-Median-PS-Value is ranked worse than 61.96% of 276
companies
in the Biotechnology industry
Industry Median: 0.63
vs NTLA: 0.77
Intellia Therapeutics (NAS:NTLA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Intellia Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
15.50
/
20.10
=
0.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intellia Therapeutics Median PS Value Related Terms
Intellia Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for Intellia Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTLA vs AUPH, OCUL, VRDN: Median PS Value Comparison
For the Biotechnology subindustry, Intellia Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 34.2419.
Intellia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.587.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intellia Therapeutics (NTLA) has a Median PS Value of $20.10 as of Jun. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Intellia Therapeutics and its competitors. This is 3692% above median its historical median of 0.53. Over the past decade, Intellia Therapeutics' Median PS Value has ranged from 0.41 to 0.80. According to the industry distribution chart, Intellia Therapeutics ranks #171 out of 276 companies in the Biotechnology industry, placing it in the top 62%.
Is Intellia Therapeutics' Median PS Value too high?
Intellia Therapeutics' current Median PS Value of $20.10 is 3692% above median its 10-year median of 0.53. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 0.80. The Biotechnology industry median Median PS Value is 0.63. Intellia Therapeutics' value of $20.10 is 3090.5% above this industry median. Based on the distribution chart, Intellia Therapeutics ranks #171 out of 276 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Median PS Value compare to AUPH and OCUL?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #171 out of 276 companies for Median PS Value. This places Intellia Therapeutics in the lower half of its industry. The industry median Median PS Value is 0.63. Intellia Therapeutics' value of $20.10 is 3090.5% above this benchmark. Historically, Intellia Therapeutics' own Median PS Value has ranged from 0.41 to 0.80 over the past decade. While the company's 10-year median is 0.53 vs. the industry median of 0.63, Intellia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intellia Therapeutics's current Median PS Value of $20.10 is 3090.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Intellia Therapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intellia Therapeutics's current Median PS Value is $20.10, which is 3692% above median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.67, compared to a current price of $15.50 — trading 25% below its estimated fair value. The current Median PS Value is $20.10, which is 3692% above median its 10-year median of 0.53 and 3090.5% above the Biotechnology industry median of 0.63. Intellia Therapeutics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Median PS Value is $20.10 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intellia Therapeutics (NTLA) Overvalued in 2026?
Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued.
The current stock price of $15.50 is trading 25% below its estimated GF Value™ of $20.67.
GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.
Key valuation signals for NTLA:
Median PS Value: $20.10 (3692% above median its 10-year median of 0.53)
GF Value™: $20.67 vs. price of $15.50 (25% below fair value)
Industry Position: 3090.5% above the Biotechnology median (#171 of 276)
No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score
Get the complete analysis for NTLA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTLA has been successfully added to your 
